On 19 August 2011, the total number of Biohit Oyj’s shares and the voting rights conferred by all shares changed as a result of a directed share issue arranged to Sartorius Lab Holding GmbH.
Following the share issue, the total number of Biohit shares is 13,615,593 and the number of series B shares 10,640,093. The company’s share capital totals EUR 2,314,650.81. Following the issue, the total number of voting rights conferred by all shares is 70 150 093.
The shares were registered in the trade register and entered in the list of Biohit’s shareholders on 29 August 2011. Trading in the new shares will begin on the stock market list of NASDAQ OMX Helsinki Ltd., together with other Biohit shares, on 30 August 2011.
Helsinki, 29 August 2011
Further information:
Jussi Heiniö, President and CEO
Tel: +358 (0) 9 773 861
jussi.heinio@biohit.com
Distribution:
NASDAQ OMX Helsinki Oy
Central storage facility (www.oam.fi)
Press
www.biohit.com
Biohit in brief:
Biohit is a globally operating Finnish biotechnology company that was established in 1988. The company’s mission is to improve human health and quality of life. The company follows a goal-directed and long-term innovation and patenting strategy.
Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective liquid handling solutions for laboratory work as well as diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract. The end users of Biohit’s products are e.g. the pharmaceutical industry, the food industry, research institutes and universities as well as the public and private healthcare sectors.
Biohit has two business segments: Liquid Handling and Diagnostics. Liquid Handling products include electronic and mechanical pipettes, disposable tips as well as pipette maintenance and calibration services. The Diagnostics business comprises products and analysis systems for the early diagnosis and prevention of gastrointestinal diseases, such as the blood-sample based GastroPanel examination for the diagnosis of stomach illnesses and associated risks, and Acetium capsules, which bind carcinogenic acetaldehyde in the stomach.
In 2010, Biohit’s net sales were MEUR 40 and the company employed approximately 400 people. Biohit is headquartered in Helsinki, Finland, and has production facilities in Helsinki, Kajaani and in Suzhou, China. It has subsidiaries in France, Germany, the UK, Russia, India, China, Japan and the USA. The company also has a representative office in Singapore. Biohit's products are also sold through about 200 distributors in 70 countries.
Biohit's Series B share is quoted on NASDAQ OMX Helsinki in the Small Cap/Healthcare group and is traded under the code BIOBV.
More information: www.biohit.com.